

Table 1. Demographic characteristics

Items (unit)		ITT, SAF		PPS		mPPS	
		Placebo group (n = 28)	MR group (n = 28)	Placebo group (n = 27)	MR group (n = 27)	Placebo group (n = 26)	MR group (n = 27)
Sex	Male	13 (46.4%)	12 (42.9%)	12 (44.4%)	11 (40.7%)	12 (46.2%)	11 (40.7%)
	Female	15 (53.6%)	16 (57.1%)	15 (55.6%)	16 (59.3%)	14 (53.8%)	16 (59.3%)
Age (years)	Mean (SD)	45.9 (11.2)	44.8 (8.2)	46.2 (11.3)	44.4 (8.0)	46.3 (11.5)	44.4 (8.0)
	Median	46.0	45.0	46.0	45.0	46.5	45.0
	Min–Max	25–71	29–59	25–71	29–59	25–71	29–59
Height (cm)	Mean (SD)	163.5 (9.7)	163.3 (9.3)	162.7 (9.0)	163.0 (9.4)	163.0 (9.1)	163.0 (9.4)
	Median	163.85	160.80	162.90	158.50	163.85	158.50
	Min–Max	146.2–184.1	150.1–178.5	146.2–179.0	150.1–178.5	146.2–179.0	150.1–178.5
Body weight (kg)	Mean (SD)	64.6 (18.3)	61.9 (12.9)	62.9 (16.3)	61.7 (13.1)	63.2 (16.5)	61.7 (13.1)
	Median	64.05	61.90	63.90	60.70	64.05	60.70
	Min–Max	38.0–116.0	43.0–95.4	38.0–116.0	43.0–95.4	38.0–116.0	43.0–95.4
BMI (kg/m²)	Mean (SD)	23.8 (4.8)	23.0 (3.2)	23.5 (4.5)	23.0 (3.2)	23.6 (4.6)	23.0 (3.2)
	Median	22.85	22.55	22.60	22.40	22.75	22.40
	Min–Max	16.4–36.2	15.9–31.3	16.4–36.2	15.9–31.3	16.4–36.2	15.9–31.3
Systolic blood pressure (mmHg)	Mean (SD)	116.0 (15.1)	113.5 (11.5)	115.4 (15.1)	113.4 (11.7)	115.2 (15.3)	113.4 (11.7)
	Median	113.5	111.5	113.0	111.0	112.5	111.0
	Min–Max	87–157	92–142	87–157	92–142	87–157	92–142
Diastolic blood pressure (mmHg)	Mean (SD)	75.5 (10.5)	74.4 (9.1)	74.8 (10.0)	74.4 (9.3)	74.5 (10.1)	74.4 (9.3)
	Median	75.0	75.0	75.0	75.0	74.5	75.0
	Min–Max	51–100	55–92	51–100	55–92	51–100	55–92
LDL-C (mg/dL)	Mean (SD)	129.5 (5.4)	129.3 (5.6)	129.3 (5.4)	129.4 (5.7)	129.1 (5.4)	129.4 (5.7)
	Median	129.50	129.50	129.00	130.00	128.50	130.00
	Min–Max	120.0–139.0	120.0–139.0	120.0–139.0	120.0–139.0	120–139	120–139
HDL-C (mg/dL)	Mean (SD)	63.7 (19.4)	70.3 (19.8)	65.0 (18.5)	70.8 (20.0)	65.5 (18.7)	70.8 (20.0)
	Median	63.50	66.00	65.00	69.00	65.00	69.00
	Min–Max	29.0–107.0	42.0–104.0	34.0–107.0	42.0–104.0	34–107	42–104
Total-C (mg/dL)	Mean (SD)	214.0 (14.1)	221.7 (24.7)	213.4 (14.0)	222.1 (25.1)	213.3 (14.2)	222.1 (25.1)
	Median	213.00	213.50	213.00	214.00	212.00	214.00
	Min–Max	190.0–250.0	185.0–301.0	190.0–250.0	185.0–301.0	190–250	185–301
LDL-C/HDL-C ratio	Mean (SD)	2.2 (0.8)	2.0 (0.5)	2.1 (0.6)	2.0 (0.5)	2.1 (0.6)	2.0 (0.5)

- Bentzon JF, Kanstrup H, et al.: Low-Density Lipoprotein Cholesterol Is Predominantly Associated With Atherosclerotic Cardiovascular Disease Events in Patients With Evidence of Coronary Atherosclerosis: The Western Denmark Heart Registry. *Circulation*. 2023, 147(14):1053-1063.
DOI: <https://doi.org/10.1161/CIRCULATIONAHA.122.061010>
5. Al-shoaibi AAA, Li Y, Song Z, Chiang C, Hirakawa Y, Saif-Ur-Rahman K, Shimoda M, et al.: Association of Low-Density Lipoprotein Cholesterol with Risk of Coronary Heart Disease and Stroke among Middle-Aged Japanese Workers: An Analysis using Inverse Probability Weighting. *J Atheroscler Thromb* 2023, 30 (5): 635-19.
DOI: <https://doi.org/10.5551/jat.63519>
 6. Mizuno K, Nakaya N, Teramoto T, Yokoyama S, Ohashi Y, Ueki A, Takahashi S, et al.: Usefulness of LDL-C-Related Parameters to Predict Cardiovascular Risk and Effect of Pravastatin in Mild-to-Moderate Hypercholesterolemia. *J Atheroscler Thromb* 2012, 19 (2): 176–185.
DOI: <https://doi.org/10.5551/jat.9183>
 7. Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, et al.; Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. *J Atheroscler Thromb*. 2023 Dec 19.
DOI: <https://doi.org/10.5551/jat.GL2022>
 8. 4. Newton J, Simmons M: Statin Induced Immune Mediated Necrotizing Myopathy: More Than Just Sore Muscles. *S D Med* 2023, 76 (1): 28–30.
 9. 5. Chin YH, Lim O, Lin C, Chan YY, Kong G, Ng CH, Chong B, et al.: Meta-analysis of the Placebo and Nocebo effects associated with Placebo treatment in randomized trials of lipid-lowering therapies. *Eur Heart J Qual Care Clin Outcomes* 2023, 9 (5): 511–519.
DOI: <https://doi.org/10.1093/ehjqcco/qcac060>
 10. Baumgartner S, Bruckert E, Gallo A, Plat J: The position of functional foods and supplements with a serum LDL-C lowering effect in the spectrum ranging from universal to care-related CVD risk management. *Atherosclerosis* 2020, 311 116–123.
DOI: <https://doi.org/10.1016/j.atherosclerosis.2020.07.019>
 11. Suzuki T, Kurokoh R, Murakami S, Takahashi N, Matsuura A, Katsu K, Murata K: Rutin Concentration and Characterization of Rutinosidase in Perennial Buckwheat (*Fagopyrum cymosum*) and Its Application in Foods. *Foods* 2023, 12 (7): 1417. DOI: <https://doi.org/10.3390/foods12071417>
 12. Iriti M, Varoni EM, Vitalini S: Bioactive Compounds in Health and Disease – Focus on Rutin. *Bioact Compd Health Dis* 2023, 6 (10): 235. DOI: <https://doi.org/10.31989/bchd.v6i10.1145>
 13. Chitrakar B, Hou Y, Devahastin S, Zhang M, Sang Y: Protocols for extraction and purification of rutin from leafy by-products of asparagus (*Asparagus officinalis*) and characterization of the purified product. *Food Chem* 2023, 418 136014.
DOI: <https://doi.org/10.1016/j.foodchem.2023.136014>
 14. Muvhulawa N, Dlodla PV, Ziqubu K, Mthembu S XH, Mthiyane F, Nkambule BB, Mazibuko-Mbeje SE, Rutin ameliorates inflammation and improves metabolic function: A comprehensive analysis of scientific literature. *Pharmacol Res*. 2022 Apr:178:106163.
DOI: <https://doi.org/10.1016/j.phrs.2022.106163>
 15. Tobar-Delgado E, Mejía-España D, Osorio-Mora O, Serna-Cock L. Rutin: Family Farming Products' Extraction Sources, Industrial Applications and Current Trends in Biological Activity Protection. *Molecules*. 2023; 28(15):5864.
DOI: <https://doi.org/10.3390/molecules28155864>
 16. Shimoi K, Yoshizumi K, Kido T, Usui Y, Yumoto T: Absorption and Urinary Excretion of Quercetin, Rutin, and α G-Rutin, a Water-Soluble Flavonoid, in Rats. *J Agric Food Chem* 2003, 51 (9): 2785–2789. DOI: <https://doi.org/10.1021/jf026108a>
 17. Nishimura M, Ohkawara T, Sato Y, Satoh H, Suzuki T, Ishiguro K, Noda T, et al.: Effectiveness of rutin-rich Tartary buckwheat (*Fagopyrum tataricum* Gaertn.) 'Manten-Kirari' in body weight reduction related to its antioxidant properties: A randomised, double-blind, placebo-controlled study. *J Funct Foods* 2016, 26 460–469.
DOI: <https://doi.org/10.1016/j.jff.2016.08.004>
 18. Bazayar H, Javid AZ, Ahangarpour A, Zaman F, Hosseini SA, Zohoori V, Aghamohammadi V, et al.: The effects of rutin supplement on blood pressure markers, some serum antioxidant enzymes, and quality of life in patients with type 2 diabetes mellitus compared with placebo. *Front Nutr*. 2023 Aug 3:10:1214420.
DOI: <https://doi.org/10.3389/fnut.2023.1214420>
 19. Hashizume Y, Tandia M: The reduction impact of monoglucosyl rutin on abdominal visceral fat: A randomized, placebo-controlled, double-blind, parallel-group. *J Food Sci* 2020, 85 (10): 3577–3589.
DOI: <https://doi.org/10.1111/1750-3841.15429>
 20. Hashizume Y, Tandia M: Suppressive effect of a single dose of monoglucosyl rutin on postprandial blood glucose elevation: A randomized, placebo-controlled, double-blind crossover study. *Funct Foods Heal Dis* 2021, 11 (6): 270.
DOI: <https://doi.org/10.31989/ffhd.v11i6.793>
 21. Suzuki N, Baba A, Kakinuma T, Sano Y, Tanaka M, Ouchi S,

- Watanabe T, et al.: A novel dietary questionnaire: The Calorie and Nutrition Diary (CAND). *New Food Ind* 2019, 61 (10): 721–732.
22. Martirosyan D, Kanya H, Nadalet C: Can functional foods reduce the risk of disease? Advancement of functional food definition and steps to create functional food products. *Functional Foods in Health and Disease* 2021, 11 (5): 213. DOI: <https://doi.org/10.31989/ffhd.v11i5.788>
23. Martirosyan D, Stratton S: Advancing functional food regulation. *Bioact Compd Health Dis* 2023, 6 (7): 166. DOI: <https://doi.org/10.31989/bchd.v6i7.1178>
24. Cohen J: A power primer. *Psychol Bull* 1992, 112 (1): 155–159. DOI: <http://dx.doi.org/10.1037/0033-2909.112.1.155>
25. Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA: The Global Burden of Cardiovascular Diseases and Risk. *J Am Coll Cardiol* 2022, 80 (25): 2361–2371. DOI: <https://doi.org/10.1016/j.jacc.2022.11.005>
26. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, et al.: 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019, 140 (11): DOI: <https://doi.org/10.1161/CIR.0000000000000677>
27. Poznyak A V., Nikiforov NG, Markin AM, Kashirskikh DA, Myasoedova VA, Gerasimova E V., Orekhov AN: Overview of OxLDL and Its Impact on Cardiovascular Health: Focus on Atherosclerosis. *Front Pharmacol* 2021, 11 DOI: <https://doi.org/10.3389/fphar.2020.613780>
28. Mhaimeed O, Burney ZA, Schott SL, Kohli P, Marvel FA, Martin SS: The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better. *Am J Prev Cardiol* 2024, 18 100649. DOI: <https://doi.org/10.1016/j.ajpc.2024.100649>
29. Albosta MS, Grant JK, Taub P, Blumenthal RS, Martin SS, Michos ED: Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease. *Vasc Health Risk Manag* 2023, Volume 19 421–431. DOI: <https://doi.org/10.2147/VHRM.S338424>
30. Agnello F, Ingala S, Laterra G, Scalia L, Barbanti M: Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management. *J Clin Med* 2024, 13 (5): 1251. DOI: <https://doi.org/10.3390/jcm13051251>
31. Hasan AA, Ahmed GMS, Hady BMA, Ahmed IH, ElSaghier EO, ElSayed MEM, Azel LH, et al.: Low-density lipoprotein-cholesterol and its relation to epicardial fat volume in patients with type II diabetes mellitus. *Bioactive Compounds in Health and Disease* 2023; 6(11): 315-324. DOI: <https://doi.org/10.31989/bchd.v6i11.1235>
32. Yokoyama D, Tanaka W, Hashizume Y, Tandia M, Sakono M, Shimoi K, Sakakibara H: Daily consumption of monoglucosyl-rutin prevents high-fat diet-induced obesity by suppressing gastric inhibitory polypeptide secretion in mice. *Functional Foods in Health and Disease*; 2018, 8 (7): 353–371. DOI: <https://doi.org/10.31989/ffhd.v8i7.527>
33. Wang W, Liu Y, Li Y, Luo B, Lin Z, Chen K, Liu Y: Dietary patterns and cardiometabolic health: Clinical evidence and mechanism. *MedComm (Beijing)* 2023, 4 (1): DOI: <https://doi.org/10.1002/mco2.212>
34. Diab A, Dastmalchi LN, Gulati M, Michos ED: A Heart-Healthy Diet for Cardiovascular Disease Prevention: Where Are We Now? *Vasc Health Risk Manag* 2023, Volume 19 237–253. DOI: <https://doi.org/10.2147/VHRM.S379874>
35. Shimizu M, Li J, Inoue J, Sato R: Quercetin Represses Apolipoprotein B Expression by Inhibiting the Transcriptional Activity of C/EBP β . *PLoS One* 2015, 10 (4): e0121784. DOI: <https://doi.org/10.1371/journal.pone.0121784>
36. Suganya S, Nandagopal B, Anbarasu A: Natural Inhibitors of HMG-CoA Reductase-An Insilico Approach Through Molecular Docking and Simulation Studies. *J Cell Biochem* 2017, 118 (1): 52–57. DOI: <https://doi.org/10.1002/jcb.25608>
37. Barkas F, Bathrellou E, Nomikos T, Panagiotakos D, Liberopoulos E, Kontogianni MD: Plant Sterols and Plant Stanols in Cholesterol Management and Cardiovascular Prevention. *Nutrients* 2023, 15 (13): 2845. DOI: <https://doi.org/10.3390/nu15132845>
38. Chanapuk R, Mungtaweepong S, Sriyakul K, Tungsukruthai P, Pattaraarchachai J, Kamalashiran C: Perilla seed oil as an adjunctive treatment with statins improves lipid profiles in elderly patients: a post hoc data analysis. *Functional Foods in Health and Disease* 2023, 13 (12): 717. DOI: <https://doi.org/10.31989/ffhd.v13i12.1258>